Ernexa Share Price

Ernexa Share Price

NASDAQ: ERNA | Micro Cap | Healthcare
$1.69
+$0.08 (4.97%) Last updated on 19 Nov, 2026 | 00:43 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Ernexa Stock Performance

Open
N/A
Prev. Close
$1.61
Circuit Range
N/A
Day Range
N/A
Year Range
$0.14 - $15.75
Volume
N/A
Average Traded
N/A

Ernexa Share Price Chart

Line chart of the Ernexa price trend over the selected period. The price rose overall, ranging from 1.69 to 1.71, ending at 1.69.
$0.00$0.00
L
Show Current Price
H

Ernexa Stock Fundamentals & Key Indicators

Market Cap
$10.66M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-8.26
Revenue (TTM)
$0.00
Return On Equity (TTM)
-321.17%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-94.70%

Ernexa Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$1.51-$5.51-$4.02-$2.94
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-264.90%27.04%26.87%

Ernexa Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$0.00$0.07$0.58$0.00
Net Profit-$24.60-$21.68-$44.56-$14.10
Net Profit MarginN/A-30971.43%-7682.76%N/A
Income ChangeN/A11.87%-105.54%68.36%

Ernexa Balance Sheet

All figures in USD Million

Particulars2025202420232022
Non Current Assets2.72.9239.538.6
Current Assets3.132.359.613.68
Total Assets5.835.2749.1322.28
Non Current Liabilities0.320.6340.332.52
Current Liabilities3.112.946.577.65
Total Liabilities3.433.5746.910.17
Shareholders' Equity2.41.72.2312.11

Ernexa Cash Flow

Annually

All figures in USD Million

Particulars2025202420232022
Operating-7.02-15.84-20.41-20.98
Investing-0.04-0.37-0.02-0.05
Financing7.216.2616.5619.58

Corporate Actions

Split
Ex-date: 04 May 2026

Split
Ex-date: 12 Jun 2025

About Ernexa

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Ernexa Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$2.00
$1.61
-22.97%
Oct 2026
$2.91
$2.09
-35.19%
Sep 2026
$4.53
$3.23
-33.09%
Aug 2026
$3.42
$4.82
+41.76%
Jul 2026
$6.65
$3.40
-49.63%
Jun 2026
$9.44
$6.75
-35.84%
May 2026
$0.15
$10.52
+7,155.17%
Apr 2026
$0.21
$0.14
-27.86%
Mar 2026
$0.29
$0.20
-31.40%
Feb 2026
$1.25
$0.29
-75.98%
Jan 2026
$1.16
$1.22
+0.00%
Dec 2025
$1.28
$1.22
-9.63%

Ernexa Share Price FAQs